Biotech industry veteran Leda Trivinos to lead expansion of firm’s internal innovation and patenting program
Cambridge, Mass., Sept. 9, 2015/PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, announced it has hired Leda Trivinos, Ph.D., as Partner, Intellectual Property. Trivinos will play a key role as Flagship scales the company creation activities of its VentureLabs innovation foundry.
“Based on recently forged innovation alliances with our corporate partners as well as the closing of our $537 million Fund V earlier this year, we are scaling our internal innovation and company creation activities and plan to launch as many as five new companies each year from VentureLabs,” said Noubar Afeyan Ph.D., senior managing partner and chief executive officer of Flagship Ventures. “Leda will play a key role crafting intellectual property strategies for VentureLabs as well as for these new ventures.”
Trivinos served most recently as chief patent counsel for Momenta Pharmaceuticals Inc., a leader in the analysis and design of complex pharmaceutical products. Prior to joining Momenta, she was assistant general counsel for intellectual property at Biogen Idec. She started her law career at Fish & Richardson PC, a global law firm specializing in intellectual property.
“I’m excited to be a part of the Flagship team, to help shepherd and protect disruptive technologies on their way towards successful company and product launches,” said Trivinos-Lagos. “Following the firm’s recent successes from internally developed innovations like the ones underlying Moderna Therapeutics, Seres Therapeutics, Symbiota and Pronutria Biosciences, I look forward to being at the center of the innovative, cutting-edge science and technologies being discovered and developed here.”
Prior to earning her law degree from the University of California Berkeley School of Law, Trivinos was awarded a Ph.D. in cell and molecular biology from Northwestern University Medical School. Her research focused on cytoplasmic dynein, a motor protein that drives intracellular transport. She also completed a post-doctoral research appointment in the lab of Suzanne R. Pfeffer Ph.D. at Stanford University’s Biochemistry Department, focusing on Rab proteins involved in membrane traffic in human cells.
About Flagship Ventures
Realizing entrepreneurial innovation is the mission of Flagship Ventures. Founded in 2000, the firm has launched 35 first-in-class companies while investing in another 55. Flagship manages over $1.4 billion in capital and is active in three principal sectors: therapeutics, health technologies, and sustainability. Flagship’s current portfolio includes Acceleron (NASDAQ: XLRN), Agios (NASDAQ: AGIO), Seres Therapeutics (NASDAQ: MCRB), T2 Biosystems (NASDAQ: TTOO), as well as several private companies: Editas Medicine, Moderna Therapeutics and Syros Pharmaceuticals. For more information, please visit www.flagshipventures.com.
About Flagship VentureLabs
Flagship VentureLabs® is the innovation foundry of Flagship Ventures. VentureLabs has been creating breakthrough companies since 2000. It is the first institution dedicated to entrepreneurial innovation, where discovery, invention and entrepreneuring are performed simultaneously by a world-class team of scientists, innovators and professional entrepreneurs. VentureLabs innovates, invents, launches and builds startups through a unique, systematic approach that produces best-in-class companies based on in-house innovations. VentureLabs has started 35 life science and technology companies, including Joule Unlimited, Seres Therapeutics (NASDAQ: MCRB), Pronutria Biosciences, Symbiota and Moderna Therapeutics. For more information, please visit www.flagshipventures.com/venturelabs.